| Methods |
Six‐week randomised, double‐blind multicentre study |
| Participants |
Patients with atypical depression according to Quitkin et al (1988) criteria
Mean age: 35 years
Exclusion criteria: not stated |
| Interventions |
Fluoxetine: 14 participants
Imipramine: 14 participants
Fluoxetine dose: 20 mg/day
Imipramine dose range: 75‐125 mg/day |
| Outcomes |
Hamilton Rating Scale for Depression (HDRS), Clinical Global Impression (CGI), Covi Anxiety Scale (CAS) |
| Notes |
Funding: unclear |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Random sequence generation (selection bias) |
Unclear risk |
Randomised, no further information |
| Allocation concealment (selection bias) |
Unclear risk |
No information provided |
| Blinding (performance bias and detection bias)
All outcomes |
Unclear risk |
Double blind, no further information |
| Blinding of participants and personnel (performance bias)
All outcomes |
Unclear risk |
Double blind, no further information |
| Blinding of outcome assessment (detection bias)
All outcomes |
Unclear risk |
Double blind, no further information |
| Incomplete outcome data (attrition bias)
All outcomes |
High risk |
Withdrawals were reported, but not included in the analysis. Scores reported without denominators. Side effects not clearly reported |
| Selective reporting (reporting bias) |
Unclear risk |
Endpoint mean scores and standard deviations reported |
| Other bias |
Unclear risk |
Funding: unclear |
